Shares of Juno Therapeutics gained nearly 10.5 percent Monday after the company released promising clinical data for one of its leukemia treatments.
The biopharmaceutical company has been developing chimeric antigen receptor technology, a line of therapies that would teach certain white blood cells how to recognize and kill cancer cells. The commercialization of the product line would have a huge effect on cancer immunotherapy because the cancer cells would be identified by proteins on the surface of the cells that are specific to it.
Juno saw optimistic results for the drug in patients with a form of leukemia where the bone marrow makes too many lymphocytes, a type of white blood cell.
Ninety percent of patients with minimal disease and 77 percent of those with an advanced form of the disease saw a complete response, also known as complete remission.